Lugano, Switzerland (ots) - As part of the Helsinn Group's
development strategy, William Mann, PhD, has been appointed as new
CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc.
William Mann, PhD, was already Chief Operating Officer of the
recently acquired Helsinn Therapeutics, and has held leadership
positions in a Swiss multinational with positions in Business
Development and in Research.
Moreover, Helsinn announces that Mr. William Brown has been hired
as Vice President Commercial Operations USA, to build a Helsinn
Therapeutics direct sales structure in the United States. Mr. Brown
has experience in multinational groups and in the management of
Supportive Care, having previously managed the product Aloxi in MGI
Dr. Riccardo Braglia, the Helsinn group's CEO said, "Helsinn
wishes to implement a new group growth strategy in the United States,
placing more and more importance on the project development and
acquisition of new business expertise. The appointments of William
Mann and William Brown will allow us to consolidate Helsinn's US
business, the projects currently in development in cancer supportive
care and in gastrointestinal areas and will lay the foundations for
further development in North America also from a commercial point of
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with
headquarters in Lugano, Switzerland, and subsidiaries in USA and
Ireland. Helsinn's unique business model is focused on the licensing
of pharmaceuticals and medical devices in therapeutic niche areas.
The Group in-licenses early stage new chemical entities, completes
their development from the performance of pre-clinical/clinical
studies and Chemistry, Manufacturing and Control (CMC) development,
to the filing for and attainment of their market approval worldwide.
Helsinn's products are sold directly, through the Group
subsidiaries, or eventually out-licensed to its network of local
marketing and commercial partners, selected for their deep in-market
knowledge and know-how, and assisted and supported with a full range
of product and scientific management services, including commercial,
regulatory, financial, legal and medical marketing advice.
The active pharmaceutical ingredients and the finished dosage
forms are manufactured at Helsinn's cGMP facilities in Switzerland
and Ireland, and supplied worldwide to its customers. Helsinn is the
worldwide licensor of palonosetron, a second generation 5-HT3
receptor antagonist, for the prevention of chemotherapy-induced
nausea and vomiting (CINV) and of post-operative nausea and vomiting
(PONV) in patients with cancer, and of the original nimesulide, a
non-steroidal anti-inflammatory drug (NSAID) distributed in more than
50 countries worldwide.
Helsinn, with a workforce of around 450 employees in Switzerland,
Ireland and USA, reported a 2008 turnover of over CHF 280.3 million
(about EUR 178 million), covering 75 countries worldwide, with over
20% of this turnover invested in R&D.
For more information about Helsinn Group, please visit the
ots Originaltext: Helsinn Healthcare SA
Head of Communication & Press Office